The average one-year price target for Alumis (NasdaqGS:ALMS) has been revised to $36.28 / share. This is an increase of 79.14% from the prior estimate of $20.25 dated December 18, 2025. The price ...

Drug maker Alumis (ALMS) is climbing 7% after investment bank Oppenheimer started coverage of the name with an Outperform rating. Why Oppenheimer Is Bullish on ALMS Due to concerns about Alumis’ cash ...

A number of startups are experimenting with what a better social app could look like. For a startup called Alms, the answer is a social network that focuses on users' well-being through participation ...

Alumis Inc. (NASDAQ:ALMS) is one of the 11 Best New Penny Stocks to Buy Right Now. On May 21, Alumis Inc. (NASDAQ:ALMS) reported that it has completed its merger with ACELYRIN, Inc. As part of this ...

Concentra Biosciences' $3/share + CVR bid for SLRN is superior to the ALMS stock-for-stock offer, presenting us with a 20% spread in favor of its bid. SLRN's remaining Phase 2 asset, Lonigutamab, has ...

Alumis, Inc. (NASDAQ:ALMS) stock is trading higher on Tuesday after the company announced it entered into a collaboration and licensing agreement with Kaken Pharmaceuticals. What To Know: Under the ...

As of February 4, 2026, the average one-year price target for Alumis is $36.28/share. The forecasts range from a low of $20.20 to a high of $52.50. The average price target represents an increase of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

View Alumis Inc. ALMS stock quote prices, financial information, real-time forecasts, and company news from CNN.

Alumis Inc. recently reported past Phase 3 ONWARD1 and ONWARD2 trial results showing envudeucitinib, its oral TYK2 inhibitor, delivered high skin clearance, rapid itch relief, and quality-of-life ...